DOCSLIB.ORG

Clinical Guidelines for Use of Depot Buprenorphine (Buvidal®

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Guidelines for Use of Depot Buprenorphine (Buvidal® Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence NSW Ministry of Health 100 Christie Street ST LEONARDS NSW 2065 Tel. (02) 9391 9000 Fax. (02) 9391 9101 TTY. (02) 9391 9900 www.health.nsw.gov.au Produced by: NSW Ministry of Health Lintzeris N, Dunlop A, Masters D (2019) Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence. NSW Ministry of Health, Sydney Australia This work is copyright. It may be reproduced in whole or in part for study or training purposes subject to the inclusion of an acknowledgement of the source. It may not be reproduced for commercial usage or sale. Reproduction for purposes other than those indicated above requires written permission from the NSW Ministry of Health. © NSW Ministry of Health 2019 SHPN (CPH) 190431 ISBN 978-1-76081-226-3 Further copies of this document can be downloaded from the NSW Health website www.health.nsw.gov.au August 2019 ii NSW Health Use of depot BPN in the treatment of opioid dependence Authors Professor Nicholas Lintzeris (BMedSci MBBS PhD FAChAM) Director Drug and Alcohol Services, South East Sydney Local Health District Discipline Addiction Medicine, Faculty of Medicine and Health Sciences, University of Sydney NSW Drug and Alcohol Clinical Research and Improvement Network Professor Adrian Dunlop (MBBS, PhD, GdipEpiBiotat, FAChAM) Director Drug and Alcohol Clinical Services, Hunter New England Local Health District School of Medicine and Public Health, Faculty of Health, University of Newcastle Hunter Medical Research Institute NSW Drug and Alcohol Clinical Research and Improvement Network Debbie Masters (BHSHM, MBA(HlthMgmt)) Quality and Planning Manager, Drug and Alcohol Clinical Services, Hunter New England Local Health District NSW Health Use of depot BPN in the treatment of opioid dependence 1 Acknowledgements The authors acknowledge input from the NSW Ministry of Health and the contributions of the following groups who reviewed and commented on drafts of these guidelines • a Consultation Working Group comprising of Phillip Bannon, Principal Advisor, Centre for Aboriginal Health, NSW Ministry of Health Bruce Battye, Director Pharmaceutical Regulatory Unit, Legal and Regulatory Services, Ministry of Health Tanya Bosch, Senior Policy Officer, Clinical Policy Unit, Alcohol and Other Drugs, NSW Ministry of Health Dr Patricia Collie (FAChAM) Mid North Coast Local Health District Julie Fagan, Nurse Unit Manager, Drug and Alcohol Services, St George Hospital, South Eastern Sydney Local Health District Aleksandar Gavrilovic (B.Pharm) Principal Pharmaceutical Officer, Monitoring & Compliance, Pharmaceutical Regulatory Unit, Legal and Regulatory Services Branch Dr Anthony Gill (FAChAM), Chief Addiction Medicine Specialist, Alcohol and Other Drugs, Centre for Population Health Prof Paul Haber, Clinical Director, Drug Health Services, Sydney Local Health District Mary Ellen Harrod, NSW Users and AIDS Association Dr Phillipa Jenkins (PhD), Policy Officer, Alcohol and Other Drugs, Centre for Population Health, NSW Ministry of Health Annemarie Jones, Nurse Unit Manager, Kempsey Opioid Substitution Treatment Clinic, Mid North Coast Local Health District Debbie Kaplan, Manager, Clinical Policy, Alcohol and Other Drugs, Centre for Population Health, NSW Ministry of Health Dr Jill Roberts (MBBS Grad.Dip.A&D.St FAChAM. FFCFM(RCPA)) Clinical Director Drug and Alcohol, Justice Health and Forensic Mental Health Network Antoinette Sedwell, Agency for Clinical Innovation Sara Shaughnessy, Mid North Coast Local Health District Kristine Smith, District Coordinator Drug and Alcohol Program, Western NSW LHD Doug Smyth, Senior Policy Officer, Clinical Policy, Alcohol and Other Drugs, Centre for Population Health, NSW Ministry of Health Dr Milana Votrubec (MB BS MA MM ME USyd, FRACGP FFPMANZCA) Royal Australian College of General Practitioners Dr Hester Wilson, (BMed (Hons) Mas. Mental Health) Royal Australian College of General Practitioners • clinicians and consumers who have participated in clinical trials using depot buprenorphine products in Australia, highlighting the essential contribution of clinical research in translational activities. • an international panel of clinicians with expertise with depot buprenorphine treatment Dr Genie L. Bailey (MD) Diplomate, American Board of Addiction Medicine Clinical Assoc Prof of Psychiatry and Human Behavior Warren Alpert Medical School of Brown University Distinguished Life Fellow, American Psychiatry Assoc, Director of Research, Director of Medications for Addiction Division Stanley Street Treatment & Resources, Massachusetts Dr Oscar DAgnone, (MD, MRCPsych) Medical Director The OAD Clinic, London Dr Michael Frost (MD, FACP, FASAM) President/Medical Director, The Frost Medical Group Dr Michelle R. Lofwall, (MD, DFASAM) University of Kentucky College of Medicine, Departments of Behavioral Science and Psychiatry, Center on Drug and Alcohol Research Dr Edward V Nunes (MD) New York State Psychiatric Institute, Columbia University Medical Center Dr Kaarlo Simojoki, (MD PhD) Medical Director A-Clinic Ltd, Finland, Addiction Medicine Professor of Practise, University of Helsinki, Finland Representatives from Camurus (manufacturers of Buvidal®) and Indivior (manufacturers of Sublocade®) have had the opportunity to provide comment on the draft guidelines, however all decisions have been made by the authors and endorsed by the consultation working group. 2 NSW Health Use of depot BPN in the treatment of opioid dependence Disclaimer This document is a general guide to appropriate practice, to be followed subject to the clinician’s judgement and patient’s preference in each individual case. The guidelines are designed to provide information to assist decision-making and is based on the best available evidence at the time of development of this publication. South Eastern Sydney and Hunter New England Local Health Districts have been reimbursed for conducting clinical trials sponsored by Camurus. Nicholas Lintzeris has served on an advisory board for Indivior and Mundipharma. Acronyms AE Adverse Events COWS Clinical Opiate Withdrawal Scale CS Consensus Statement DDIs Drug Drug Interactions Depot BPN Depot Buprenorphine FC FluidCrystal® IUGR Intrauterine Growth Restriction LAI BPN Long Acting Injection Buprenorphine LFT Liver Function Test MAOIs Monoamine Oxidase Inhibitors MATOD Medication-Assisted Treatment of Opioid Dependence NAS Neonatal Abstinence Syndrome NOWS Neonatal Opioid Withdrawal Syndrome NTX Naltrexone OAT Opioid Agonist Treatment OUD Opioid Use Disorder SC Subcutaneous SL BPN Sublingual Buprenorphine SL BPN NX Sublingual Buprenorphine / Naloxone TGA Therapeutic Goods Administration NSW Health Use of depot BPN in the treatment of opioid dependence 3 Contents Acronyms .......................................................................................................................................3 Background to guideline for depot BPN for the treatment opioid dependence .............. 9 1. Introduction to opioid agonist treatment (OAT) with depot BPN medications ......10 a. Overview of treatment model of care .................................................................................................10 b. Evidence of efficacy of depot BPN in the treatment of opioid dependence ....................... 11 2. Clinical pharmacology ........................................................................................................... 12 a. Formulations ................................................................................................................................................. 12 i. Buvidal® formulations ......................................................................................................................... 12 ii. Sublocade® formulations .................................................................................................................. 12 b. Overview of pharmacokinetic properties .......................................................................................... 12 i. Absorption and onset of effects .................................................................................................... 14 ii. Metabolism ............................................................................................................................................. 14 iii. Elimination and duration of effects.................................................................................................... 14 iv. Withdrawal, cravings, opioid blockade ....................................................................................... 15 c. Side effects and safety issues ................................................................................................................ 15 i. Adverse events ..................................................................................................................................... 15 ii. Contraindications................................................................................................................................. 15 d. Special Warnings ......................................................................................................................................... 16 i. Risk of serious harm or death with intravenous administration ........................................ 16 ii. Risk of respiratory and central nervous system (CNS) depression ................................. 16 iii.
Load more

Recommended publications
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
    [Show full text]
  • Annual Report 2013
    Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD.
    [Show full text]
  • Other Statutory Disclosures Continued
    Other statutory disclosures continued Strategic reportGroup companies Governance & remuneration Financial statements In accordance with Section 409 of the Companies Act 2006 a full list of subsidiaries, associates, joint ventures and joint arrangements, the country of incorporation and effective percentage of equity owned, as at 31 December 2015 are disclosed below. Unless otherwise stated the share capital disclosed comprises ordinary shares which are indirectly held by GlaxoSmithKline plc. All subsidiary companies are resident for tax purposes in their country of incorporation unless otherwise stated. Country of Effective % % Held by Name incorporation Ownership Security Class of Share Wholly owned subsidiaries 1506369 Alberta ULC Canada 100 Common 100 Action Potential Venture Capital Limited England & Wales 100 Ordinary 100 Adechsa GmbH Switzerland 100 Ordinary 100 Affymax Research Institute United States 100 Common 100 Alenfarma – Especialidades Farmaceuticas, Limitada (iv) Portugal 100 Ordinary Quota 100 Allen & Hanburys Limited (iv) England & Wales 100 Ordinary 100 Allen & Hanburys Pharmaceutical Nigeria Limited Nigeria 100 Ordinary 100 Allen Farmaceutica, S.A. Spain 100 Ordinary 100 Allen Pharmazeutika Gesellschaft m.b.H. Austria 100 Ordinary 100 Aners S.A (iv) Argentina 100 Non-endorsable Nominative Ordinary 100 Barrier Therapeutics, Inc. United States 100 Common 100 Beecham Group p l c England & Wales 100 20p Shares 'A'; 5p Shares B 100 Beecham Pharmaceuticals (Pte) Limited Singapore 100 Ordinary 100 Beecham Pharmaceuticals S.A (iv) (vi) Ecuador 100 Nominative 100 Beecham Portuguesa-Produtos Farmaceuticos e Quimicos, Lda Portugal 100 Ordinary Quota 100 Beecham S.A. (iv) Belgium 100 Ordinary 100 Biddle Sawyer Limited India 100 Equity 100 Biovesta Ilaçlari Ltd. Sti. Turkey 100 Nominative 100 Burroughs Wellcome & Co (Australia) Pty Limited (iv) (vi) Australia 100 Ordinary 100 Burroughs Wellcome & Co (Bangladesh) Limited Bangladesh 100 Ordinary 100 Burroughs Wellcome International Limited England & Wales 100 Ordinary 100 Caribbean Chemical Company, Ltd.
    [Show full text]
  • Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
    GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
    [Show full text]
  • Annual Report 2008 Find out More About GSK Online…
    Do more, feel better, live longer Grow Deliver Simplify Annual Report 2008 Find out more about GSK online… www.gsk.com Website GlaxoSmithKline’s website www.gsk.com gives additional information on the Group. Information made available on the website does not constitute part of this Annual Report. Notice regarding limitations on Director liability under English Law Under the UK Companies Act 2006, a safe harbour limits the liability of Directors in respect of statements in and omissions from the Report of the Directors contained on pages 12 to 98. Under English law the Directors would be liable to the company (but not to any third party) if the Report of the Directors contains errors as a result of recklessness or knowing misstatement or dishonest concealment of a material fact, but would not otherwise be liable. Report of the Directors Pages 12 to 98 inclusive consist of a Report of the Directors that has been drawn up and presented in accordance with and in reliance upon English company law and the liabilities of the Directors in connection with that report shall be subject to the limitations and restrictions provided by such law. Cautionary statement regarding forward-looking statements The Group’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document and written information released, or oral statements made, to the public in the future by or on behalf of the Group, may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. A shareholder can identify these statements by the fact that they do not relate strictly to historical or current facts.
    [Show full text]
  • Glaxosmithkline Annual Report 2010
    Do more, feel better, live longer GlaxoSmithKline Annual Report 2010 Contents Business review P08–P57 Business review 2010 Performance overview 08 Research and development 10 Pipeline summary 12 Products, competition and intellectual property 14 Regulation 18 Manufacturing and supply 19 Business review World market 20 This discusses our financial and non-financial activities, GSK sales performance 21 resources, development and performance during 2010 Segment reviews 22 and outlines the factors, including the trends and the Responsible business 29 principal risks and uncertainties, which are likely to Financial review 2010 34 affect future development. Financial position and resources 41 Financial review 2009 47 Governance and remuneration Risk factors 53 This discusses our management structures and governance procedures. It also sets out the Governance and remuneration P58–P101 Governance and remuneration Governance and remuneration remuneration policies operated for our Directors and Our Board 58 Corporate Executive Team members. Our Corporate Executive Team 60 Governance and policy 64 Financial statements Dialogue with shareholders 69 The financial statements provide a summary of the Internal control framework 71 Group’s financial performance throughout 2010 and its Committee reports 74 position as at 31st December 2010. The consolidated Remuneration policy 84 financial statements are prepared in accordance with Director terms and conditions 91 IFRS as adopted by the European Union and also IFRS as Director and Senior Management remuneration 94 issued by the International Accounting Standards Board. Directors’ interests 96 Directors’ interests in contracts 101 Shareholder information This includes the full product development pipeline and discusses shareholder return in the form of dividends and share price movements.
    [Show full text]
  • Other Statutory Disclosures Continued
    272 GSK Annual Report 2016 Other statutory disclosures continued Group companies In accordance with Section 409 of the Companies Act 2006 a full list of subsidiaries, associates, joint ventures and joint arrangements, the address of the registered office and effective percentage of equity owned, as at 31 December 2016 are disclosed below. Unless otherwise stated the share capital disclosed comprises ordinary shares which are indirectly held by GlaxoSmithKline plc. The percentage held by class of share is stated where this is less than 100%. Unless otherwise stated, all subsidiary companies have their registered office in their country of incorporation. All subsidiary companies are resident for tax purposes in their country of incorporation unless otherwise stated. Name Security Registered address Wholly owned subsidiaries 1506369 Alberta ULC Common 3500 855-2nd Street SW, Calgary, AB, T2P 4J8, Canada Action Potential Venture Capital Limited Ordinary 980 Great West Road, Brentford, Middlesex, TW8 9GS, England Adechsa GmbH (iv) Ordinary c/o PRV Provides Treuhandgesellschaft AG, Dorfstrasse 38, Baar, 6341, Switzerland Affymax Research Institute Common Corporation Service Company, 2710 Gateway Oaks Drive, Suite 150N, Sacramento, California, CA, 95833, United States Alenfarma – Especialidades Farmaceuticas, Ordinary Quota Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, Alges, Limitada (iv) 1495-131, Portugal Allen & Hanburys Limited (iv) Ordinary 980 Great West Road, Brentford, Middlesex, TW8 9GS, England Allen & Hanburys Pharmaceutical Nigeria Limited Ordinary 24 Abimbola Way, Ilasamaja, Isolo, Lagos, Nigeria Allen Farmaceutica, S.A. Ordinary Severo Ochoa, 2, Parque Tecnologico de Madrid, Tres Cantos, Madrid, 28760, Spain Allen Pharmazeutika Gesellschaft m.b.H. Ordinary Wagenseilgasse 3, Euro Plaza, Gebäude I, 4.
    [Show full text]
  • Mechanisms of Cocaine Abuse and Toxicity
    Mechanisms of Cocaine Abuse and Toxicity U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration I Mechanisms of Cocaine Abuse and Toxicity Editors: Doris Clouet, Ph.D. Khursheed Asghar, Ph.D. Roger Brown, Ph.D. Division of Preclinical Research National Institute on Drug Abuse NIDA Research Monograph 88 1988 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. MARY L. JACOBSON Temple University School of Medicine National Federation of Parents for Philadelphia,Pennsylvania Drug-Free Youth Omaha, Nebraska SYDNEY ARCHER, Ph.D. Rensselaer Polytechnic lnstitute Troy, New York REESE T. JONES, M.D. Langley Porter Neuropsychiatric lnstitute RICHARD E. BELLEVILLE, Ph.D. San Francisco, California NB Associates, Health Sciences RockviIle, Maryland DENISE KANDEL, Ph.D. KARST J. BESTEMAN College of Physicians and Surgeons of Alcohol and Drug Problems Association Columbia University of North America New York, New York Washington, D.C. GILBERT J.
    [Show full text]
  • Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG
    EN Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG Only the English text is available and authentic. REGULATION (EEC) No 4064/89 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 11/01/2001 Also available in the CELEX database Document No 301M2192 Office for Official Publications of the European Communities L-2985 Luxembourg COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 11.01.2001 SG(2000)D/285020 In the published version of this decision, some PUBLIC VERSION information has been omitted pursuant to Article 17(2) of Council Regulation (EEC) No 4064/89 concerning non-disclosure of business secrets and other confidential information. The omissions are MERGER PROCEDURE shown thus […]. Where possible the information ARTICLE 6(1)(b) DECISION omitted has been replaced by ranges of figures or a general description. To the notifying party Dear Sir/Madam, Subject: Case No COMP/M.2192 – SmithKline Beecham/Block Drug Notification of 17.11.2000 pursuant to Article 4 of Council Regulation No 4064/89 1. On 17 November, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 (“the Merger Regulation”), by which the UK company, SmithKline Beecham plc (“SB”) notified its intention to acquire sole control over the US company, Block Drug Company Inc. (“Block Drug”), through purchase of shares. 2. Following examination of the notification, the Commission has concluded that the notified operation falls within the scope of the said Council Regulation and does not raise serious doubts as to its compatibility with the common market and the EEA agreement.
    [Show full text]
  • UR-Coeus Sponsor List
    UR-Coeus Sponsor Table (alphabetical by sponsor name) Sponsor Sponsor Code Sponsor Type 2138 21st Century Medicine CORP Sponsor Type Key 1 3M CORP CORP = Corporate 3803 4S3 Bioscience Inc CORP FED = Federal 5207 A. F. Associates Family Medicine ONFA FND = Foundation 2602 A. P. Pharma CORP IND = Individuals 2 A.L. Mailman Foundation FND NYS = New York State 2023 AA Implant Dentistry Research Foundation ONFA OLG = Other Local Gov't 3 AAA Fnd for Traffic Safety ONFA ONFA = Other Non-Fed Agency 2329 aaiPharma Inc CORP VHA = Voluntary Health Agency 3257 Aamjiwnaang First Nations Community ONFA 5345 Aarhus University Hospital ONFA 3713 Aaron Copland Fund for Music, Inc. ONFA 4 AARP Andrus Fdn FND 3853 AB Sciences CORP 3378 AB Vector, Inc CORP 899 Abbott Diagnostics CORP 3864 Abbott Fund FND 14 Abbott Laboratories CORP 5126 AbbVie, Inc. CORP 5854 Abeona Therapeutics CORP 5063 Abington Medical Specialists ONFA 5331 Abington Memorial Hospital ONFA 2835 ABIOMED, Inc. CORP 3687 Ablation Frontiers CORP 5118 Ablynx NV CORP 2053 ABMRF/Fnd for Alcohol Research ONFA 2171 Abortion Rights Mobilization ONFA 3361 Abraxix BioScience, LLC CORP 4953 Abt Associates, Inc. CORP 5037 Academic Gastrointestinal Cancer Consortium ONFA 15 Academic Med Ctr Cons ONFA 3733 Academic Pediatric Association ONFA 3160 Academy of Orofacial Pain ONFA 2122 Academy of Prosthodontics Foundation ONFA 3663 Acadia Pharmaceuticals, Inc. CORP 3273 Accelerate Brain Cancer Cure ONFA 5584 Acceleron Pharma Inc. CORP 5601 Accelovance, Inc. CORP 5940 Accreditation Council Grad Med Educ ONFA 5832 Accriva Diagnostics CORP 3888 AccuGenomics, Inc. CORP 5656 Acerta Pharma CORP 6101 Acessa Health, Inc.
    [Show full text]
  • Group Companies
    Strategic report Governance and remuneration Financial statements Investor information Other statutory disclosures continued Group companies In accordance with Section 409 of the Companies Act 2006 a full list of subsidiaries, associates, joint ventures and joint arrangements, the address of the registered office and effective percentage of equity owned, as at 31 December 2019 are disclosed below. Unless otherwise stated the share capital disclosed comprises Ordinary shares which are indirectly held by GlaxoSmithKline plc. The percentage held by class of share is stated where this is less than 100%. Unless otherwise stated, all subsidiary companies have their registered office and are tax resident in their country of incorporation. Name Security Registered address Wholly owned subsidiaries 1506369 Alberta ULC Common 3500 855-2nd Street SW, Calgary, AB, T2P 4J8, Canada Action Potential Venture Capital Limited Ordinary 980 Great West Road, Brentford, Middlesex, TW8 9GS, England Adechsa GmbH (ii) Ordinary c/o PRV Provides Treuhandgesellschaft AG, Dorfstrasse 38, Baar, 6341, Switzerland Affymax Research Institute Common Corporation Service Company, 2710 Gateway Oaks Drive, Suite 150N, Sacramento, California, 95833, United States Alenfarma – Especialidades Farmaceuticas, Limitada (ii) Ordinary Quota Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, Alges, 1495-131, Portugal Allen & Hanburys Limited (ii) Ordinary 980 Great West Road, Brentford, Middlesex, TW8 9GS, England Allen & Hanburys Pharmaceutical Nigeria Limited Ordinary 24 Abimbola Way, Ilasamaja, Isolo, Lagos, Nigeria Allen Farmaceutica, S.A. Ordinary Severo Ochoa, 2, Parque Tecnologico de Madrid, Tres Cantos, Madrid, 28760, Spain Allen Pharmazeutika Gesellschaft m.b.H. Ordinary Wagenseilgasse 3, Euro Plaza, Gebäude I, 4. Stock, Vienna, A-1120, Austria Barrier Therapeutics, Inc.
    [Show full text]
  • Identification and Characterization of Novel
    IDENTIFICATION AND CHARACTERIZATION OF NOVEL ANTIRETROVIRAL COMPOUNDS: FROM SMALL MOLECULE LIBRARY SCREENING TO RATIONALLY DESIGNED COMPOUNDS A dissertation submitted to Kent State University in cooperation with the Lerner Research Institute, Cleveland Clinic Foundation in partial fulfillment of the requirements For the degree of Doctor of Philosophy By Oyebisi Jegede August, 2007 Dissertation written by Oyebisi Jegede M.B.B.S., University of Ilorin, 1998 Ph.D., Kent State University, 2007 Approved by _______________, Dr. Miguel Quiñones-Mateu, Chair, Doctoral Dissertation Committee _______________, Dr. Chun-Che Tsai, Co-Chair, Doctoral Dissertation Committee _______________, Dr. Philip Pellett, Member, Doctoral Dissertation Committee _______________, Dr. Gail Fraizer, Member, Doctoral Dissertation Committee _______________, Dr. Arvind Bansal, Outside Discipline Member _______________, Dr. Mary Cismowski, Graduate Faculty Representative Accepted by _______________, Dr. Robert V. Dorman, Director, School of Biomedical Sciences _______________, Dr. John Stalvey, Dean, College of Arts and Sciences ii TABLE OF CONTENTS LIST OF FIGURES…………………………………..………….…….……..............…vi LIST OF TABLES………………………………………………………...….....……....ix ABBREVIATIONS……………………………………………………….……………...x ACKNOWLEDGEMENTS …………………………………..……………….……....xv DEDICATION………………………………………………..……………….……....xvii CHAPTER I: GENERAL INTRODUCTION………………….……………...…...…1 CHAPTER II: IDENTIFICATION AND CHARACTERIZATION OF NOVEL ANTIRETROVIRAL COMPOUNDS FROM HIGH-THROUGHPUT SCREENING OF SMALL
    [Show full text]